

EXHIBIT 2

[BLOG](#)[ABOUT US](#)[CAREERS](#)[INVESTORS](#)[CONTACT US](#)[LOGINS](#)

Search

Search

[Pharmaceutical
Distribution](#)[Wholesale Medical
Supplies](#)[Pharmacy Services &
Technology](#)[Specialty Practice
Solutions](#)[Solutions for
Biopharma](#)[HOME](#) / [ABOUT MCKESSON](#) / [OPIOID ABUSE - FIGHTING THE EPIDEMIC](#)

Opioid Abuse - Fighting the Epidemic

[HOME](#)[60 MINUTES RESPONSE](#)[HOW WE'RE FIGHTING THE EPIDEMIC](#)[POLICY RECOMMENDATIONS](#)[PRESCRIPTION SAFETY-ALERT SYSTEM](#)[CONTROLLED SUBSTANCE MONITORING PROGRAM](#)[PHARMACEUTICAL SUPPLY CHAIN](#)[PERSPECTIVES AND STATEMENTS](#)[OPIOID FOUNDATION](#)[FACT SHEETS](#)[BOARD RESPONSE](#)

At McKesson, we take our role in helping to protect the safety and integrity of the pharmaceutical supply chain extremely seriously.

On December 16, 2018, 60 Minutes aired a segment profiling the plaintiff lawyers who are leading the lawsuits against the companies that manufacture and distribute prescription opioids. We were disappointed that 60 Minutes chose to present a one-sided story, which uncritically repeated the plaintiffs' lawyers' charges without any challenge. We encourage you to visit our [60 Minutes Response](#) page, where we've prepared a short Q&A to address several misconceptions about the opioid epidemic, the role distributors play in the industry, and what McKesson is doing to help address the crisis.

As a company, we are deeply concerned by the impact the opioid epidemic is having on families and communities across our nation—and we're committed to being part of the solution. We have formed an independent foundation, to which McKesson contributed \$100 million, dedicated to addressing the crisis. We are also advancing [company initiatives](#) aimed at preventing opioid abuse and offering thoughtful [public policy recommendations](#), including the [Prescription Safety-Alert System](#) (RxSAS) technology proposal. We encourage you to learn more by exploring the information available in the website tabs above.

Each day, our distribution team delivers life-saving medicines to pharmacies, hospitals and clinics that serve millions of Americans. We take to heart that each and every item delivered – every pill bottle, every vial, every ointment – reaches a patient in need. We know that it's not just a package, it's a patient.

Over the past decade, as the opioid epidemic evolved rapidly, we enhanced our teams, processes and technologies dedicated to preventing diversion. We are committed to maintaining – and continuously enhancing – [strong programs](#) designed to detect and prevent opioid diversion within the pharmaceutical supply chain, while also protecting the availability of appropriate treatments for patients with serious illnesses and injuries.

This complicated, multi-faceted public health crisis must be addressed through a comprehensive and collaborative approach. Each participant in the **pharmaceutical supply chain** can play an important role, including:

- The Drug Enforcement Administration (DEA), which has regulatory oversight for all DEA-registrants (doctors, pharmacists, distributors) and sets yearly quotas for the volume of opioids that can be manufactured
- Drug manufacturers that design, develop and promote the medication
- Doctors who prescribe the medication
- Pharmacists who dispense the medication
- Private and public health insurance groups that determine what they will pay for
- State medical and pharmacy boards that oversee the doctors and pharmacies in their jurisdiction
- Distributors that deliver medications ordered by pharmacists to fill prescriptions written by doctors

Today, we are working with others to advance a series of **company initiatives** focused on helping to address the opioid epidemic, support the formation of a foundation dedicated to combating the crisis, offer thoughtful **public policy recommendations** – including the Prescription Safety-Alert System (RxSAS) technology proposal – and to support **innovative programs and partnerships** that we believe can have a meaningful impact on this challenging issue. We are committed to engaging with all who share our dedication to acting with urgency to address this epidemic and working together to end this national crisis. We encourage you to click through to the tabs above to learn more about our response to the opioid crisis.

Opioid Resources

McKesson's Opioid Initiatives, New Foundation

Learn more about how McKesson's new company initiatives will help fight the opioid epidemic, including the formation of a foundation dedicated to combating the crisis.

[LEARN MORE](#)

Pharmaceutical Supply Chain

McKesson works closely with pharmacies and manufacturers to ensure pharmacies have the medications their patients need. See how medications move through the supply chain.

[LEARN MORE](#)

Controlled Substance Monitoring Program

Our CSMP uses sophisticated algorithms designed to monitor for suspicious orders, and block the shipment of controlled substances.

[LEARN MORE](#)

Opioid Policy Recommendations

McKesson has offered policy recommendations that can improve prescribing and dispensing practices, limit the supply of opioids and facilitate better information sharing.

[LEARN MORE](#)

Partnering Against Opioid Abuse

The opioid epidemic won't be solved by any one participant or idea. McKesson is partnering with others to deploy the best thinking across the country and advance meaningful solutions.

[LEARN MORE](#)



ABOUT MCKESSON

[About Us](#)
[Our Values](#)
[Locations](#)
[McKesson Vision Centers](#)
[Corporate Social Responsibility](#)
[Newsroom](#)
[Event Calendar](#)
[Connect With McKesson](#)

BLOG

CAREERS

[Find A Job](#)
[Campus Recruiting](#)

POPULAR SOLUTIONS

[Medical Supplies](#)
[Pharmaceutical Distribution](#)
[Specialty Drug Distribution](#)
[Health Mart Independent Pharmacy](#)
[Pharmacy Services & Technology](#)

RESOURCES

[Biopharma Resources](#)
[Explainer: Biosimilars](#)
[Explainer: Medication Dispensing](#)
[Explainer: Unit Dose Packaging](#)

CUSTOMER ORDERING

[Pharmaceuticals: Branded & Generic](#)
[Specialty and Oncology Drugs](#)
[Plasma Products](#)
[Medical Supplies & Equipment](#)
[Homecare Products for Consumers](#)

INVESTORS

[Financial News](#)
[Events](#)
[Financial Information](#)
[Stock Information](#)
[Investor Alerts](#)
[Corporate Governance](#)

OUR BUSINESSES

[U.S. Pharmaceutical](#)
[Medical-Surgical](#)
[Specialty Health](#)
[Pharmacy Systems](#)
[High Volume Solutions](#)
[RelayHealth](#)
[Life Sciences](#)

MCKESSON INTERNATIONAL

[McKesson Canada](#)
[McKesson Europe](#)

MCKESSON VENTURES

[CONTACT US](#) [PRIVACY NOTICE](#) [DISCLAIMER](#) [PATENTS](#) [SITE MAP](#)
© 2019 McKesson Corporation